Quel est le prix pour Beta Bionics, Inc. (BBNX)

Le prix pour Beta Bionics, Inc. (BBNX) est $19.81

Quelle est la capitalisation boursière pour Beta Bionics, Inc. (BBNX)

La capitalisation boursière pour Beta Bionics, Inc. (BBNX) est $891.32M

Beta Bionics, Inc. (BBNX) Ratio P/B

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Année	Ratio P/B	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/B

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/B	Différence de Ratio P/B	Pays
Abbott Laboratories ABT.US	3.7944	-	US
Stryker Corporation SYK.US	5.423	-	US
Medtronic plc MDT.US	2.0146	-	IE
Boston Scientific Corporation BSX.US	3.072	-	US
Siemens Healthineers AG SHL.DE	-	-	DE

Entreprise

Ratio P/B

Différence de Ratio P/B

Pays